Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EVOK

EVOK - Evoke Pharma Inc Stock Price, Fair Value and News

$25.25-0.10 (-0.39%)
Market Closed

40/100

EVOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

40/100

EVOK

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$25.14

Target 3M

$28.29

Target 6M

$27.2

EVOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EVOK Price Action

Last 7 days

-3.8%

Last 30 days

15.8%

Last 90 days

-39.9%

Trailing 12 Months

-64.0%

EVOK RSI Chart

EVOK Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EVOK Valuation

Market Cap

43.7M

Price/Earnings (Trailing)

-8.35

Price/Sales (Trailing)

3.03

Price/Free Cashflow

-13.13

EVOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$25.14

Target 3M

$28.29

Target 6M

$27.2

EVOK Fundamentals

EVOK Revenue

Revenue (TTM)

14.4M

Rev. Growth (Yr)

61.4%

Rev. Growth (Qtr)

14.17%

EVOK Earnings

Earnings (TTM)

-5.2M

Earnings Growth (Yr)

11.9%

Earnings Growth (Qtr)

26.4%

EVOK Profitability

Return on Equity

-155.44%

Return on Assets

-33.39%

Free Cashflow Yield

-7.61%

EVOK Investor Care

Shares Dilution (1Y)

15.91%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202511.6M12.8M14.4M0
20246.1M7.5M8.6M10.2M
20232.9M3.6M4.3M5.2M
20221.9M2.2M2.1M2.5M
2021111.9K347.4K1.3M1.6M
202000023.0K
20157.7K5.6K4.3K0
20149.9K12.3K13.4K10.2K
20133.1K4.5K5.9K7.2K
2012006.2K1.7K
201100010.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Evoke Pharma Inc

EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
 CEO
 WEBSITEhttps://evokepharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES4

Evoke Pharma Inc Frequently Asked Questions

EVOK is the stock ticker symbol of Evoke Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Evoke Pharma Inc is 43.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EVOK's fair value in chart for subscribers.

The fair value guage provides a quick view whether EVOK is over valued or under valued. Whether Evoke Pharma Inc is cheap or expensive depends on the assumptions which impact Evoke Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EVOK.

As of Wed Jan 28 2026, EVOK's PE ratio (Price to Earnings) is -8.35 and Price to Sales (PS) ratio is 3.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EVOK PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Evoke Pharma Inc has provided -0.176 (multiply by 100 for percentage) rate of return.